Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 30, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell

This study investigated the cost-effectiveness of different approaches to treat rheumatoid arthritis.

They found that csDMARDs are as effective as TNF inhibitors and cost less. 

Some background

Treating rheumatoid arthritis (RA) involves reducing inflammation. Inflammation leads to painful swelling and joint damage. Disease-modifying anti-rheumatic drugs (DMARDs) are used to treat RA. Methotrexate (MTX) is the first line of treatment for RA. Other drugs may be combined with MTX to improve the response. Synthetic DMARDs (csDMARDs) or tumor necrosis factor inhibitors (TNFis) are usually prescribed. Both of these medications are clinically effective. csDMARDs are chemical drugs. TNFis are a type of drug called biologics. Biologic drugs (BDs) are more expensive than csDMARDs. 

Affordability is an important consideration when selecting a medication. Although TNFis are effective, it is not clear if the benefit outweighs the cost compared to csDMARDs.

Methods & findings

This study included 205 patients with RA. The trial lasted 12 months. Patients were taking either csDMARDs or TNFis. They were taken in combination with MTX. Patients in the TNFi group were taking one TNFi. Patients in the csDMARD group were taking several DMARDs. Participants with a poor response to DMARDs were offered TNFis. The cost of treatment per participant was measured. The effectiveness of treatment was measured using a standardized questionnaire.

DMARDs were associated with lower cost and better patient outcomes at 12 months. Overall, csDMARD treatment also required less resource use. The results were similar across a number of factors including age and duration of illness. 

The bottom line

The authors concluded that starting treatment with csDMARDs rather than TNFis is more cost-effective and with similar outcomes.

The fine print

This study investigated a relatively short time period. As RA is a chronic illness, the cost of treatment may be greater over time. More investigation is needed.

What’s next?

If you have any concerns regarding RA treatment, please consult with your physician. 

Published By :

Arthritis Care & Research

Date :

Jan 10, 2019

Original Title :

Cost-effectiveness of combination disease-modifying antirheumatics vs. tumour necrosis factor inhibitors in active rheumatoid arthritis: TACIT trial.

click here to get personalized updates